BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shanker MD, Liu HY, Lee YY, Stuart KA, Powell EE, Wigg A, Pryor DI. Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium. J Gastroenterol Hepatol 2021;36:873-84. [PMID: 32632941 DOI: 10.1111/jgh.15175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Parikh ND, Cuneo K, Mendiratta-Lala M. Radiation Therapies for the Treatment of Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2021;17:341-6. [PMID: 34136139 DOI: 10.1002/cld.1060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Shanker MD, Moodaley P, Soon W, Liu HY, Lee YY, Pryor DI. Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of local control, survival and toxicity outcomes. J Med Imaging Radiat Oncol 2021. [PMID: 34396706 DOI: 10.1111/1754-9485.13309] [Reference Citation Analysis]
3 Kotsifa E, Vergadis C, Vailas M, Machairas N, Kykalos S, Damaskos C, Garmpis N, Lianos GD, Schizas D. Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How? JPM 2022;12:436. [DOI: 10.3390/jpm12030436] [Reference Citation Analysis]
4 Yang KL, Chi MS, Ko HL, Huang YY, Huang SC, Lin YM, Chi KH. Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial. Radiat Oncol 2021;16:18. [PMID: 33472666 DOI: 10.1186/s13014-020-01742-w] [Reference Citation Analysis]
5 Ohkoshi-Yamada M, Kamimura K, Shibata O, Morita S, Kaidu M, Nakano T, Maruyama K, Ota A, Saito H, Yamana N, Oshikane T, Goto Y, Yoshimura N, Tanabe S, Nakano H, Sakai M, Tanaka Y, Koseki Y, Arao Y, Abe H, Setsu T, Sakamaki A, Yokoo T, Kamimura H, Aoyama H, Terai S. Efficacy and Safety of the Radiotherapy for Liver Cancer: Assessment of Local Controllability and its Role in Multidisciplinary Therapy. Cancers (Basel) 2020;12:E2955. [PMID: 33066141 DOI: 10.3390/cancers12102955] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Facciorusso A, Chierici A, Cincione I, Sacco R, Ramai D, Mohan BP, Chandan S, Ofosu A, Cotsoglou C. Stereotactic body radiotherapy vs radiofrequency ablation for the treatment of hepatocellular carcinoma: a meta-analysis. Expert Rev Anticancer Ther 2021;21:681-8. [PMID: 33590783 DOI: 10.1080/14737140.2021.1891887] [Reference Citation Analysis]
7 Chang Q, Xu Y, Wang J, Jing H, Rao L, Tang W, Zhang Z, Wu X. SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma. Comput Math Methods Med 2021;2021:8556888. [PMID: 34819993 DOI: 10.1155/2021/8556888] [Reference Citation Analysis]